BioCopy is a leading brand in the field of next-level drug discovery in immuno-oncology. With a focus on T-cell therapeutics, they offer innovative solutions to accelerate lead discovery for HLA binding. Their cutting-edge microarray technology enables efficient immune profiling and lead screening of T-cell receptors (TCR), bi- and multispecifics, and other biomolecules against thousands of antigen-HLA complexes in parallel.

BioCopy's ValidaTe technology is a high-throughput screening method that provides detailed binding kinetic data sets, empowering drug developers with in-depth insights at every step of the drug discovery process. They also specialize in microarrays fabrication, offering tailor-made solutions for binding kinetic measurement of various analytes. Additionally, BioCopy's Label-free kinetics technology, utilizing Single Color Reflectometry (SCORE), enables ultra-high throughput analysis of molecular binding interactions.

In the realm of drug discovery in immuno-oncology, BioCopy stands out as a trusted partner, driven by innovation and a commitment to advancing therapeutic advancements